AllDocs -> cancers

What You Need To Know About Multiple Myeloma U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute ™ What You Need To Know About Index Page 2 This booklet is about multiple myeloma . The Cancer Information Service can help you learn more about this disease. The staff can talk with you in English or Spanish. The number is 1–800–4–CANCER (1–800–422–6237). The number for callers with TTY equipment is 1–800–332–8615. Your call is free. Este folleto es acerca del mieloma múltiple. Llame al Servicio de Información sobre el Cáncer para saber más sobre esta enfermedad. Este servicio tiene personal que habla español. El número a llamar es el 1–800–4–CANCER (1–800–422–6237). Personas con ...

143 Colon and Rectum Summary Male Female Utah 1996-2000 US 1996-99 Utah 1996-2000 US 1996-99 Average annual age-adjusted incidence rates* 7.6 6.8 3.5 4.6 Rank among cancer incidence rates 12 14 16 16 Average annual number of new cases 48 7,710 29 7,000 Percent of all new cancer cases 1.5 % 1.2 % 1.0 % 1.1 % * Rates per 100,000 and standardized to the 2000 U.S. population Lifetime risk of this cancer (00-79 years) 1 in 130 1 in 142 1 in 267 1 in 205 Average annual age-adjusted mortality rates* 5.4 4.8 3.5 3.3 Rank among cancer mortality rates 8 12 9 10 Average annual number of deaths 32 5,286 28 5,057 Percent of all cancer deaths 2.7 % 1.9 % ...

• First treatment modality in MM patients was 87% HD and 13% PD, without difference between age groups. Only 1.1% received a transplant while on RRT. • Figure 3 shows the crude patient survival of MM patients compared to other dialysis patients. Median survival in the MM group was 11 months. Main causes of death were: malignancy 38%, cardiovascular 16% and infection 16%. • Figure 4 shows that, adjusted for age and gender, MM patients had a 2.8 times (95%CI 2.6-3.0) higher risk of death compared to other dialysis patients. Adjusted dialysis patient survival did not change with time. Results • 906 patients started RRT for MM, median age 68 year, 57% male. • Mean age at start of RRT increased from 64 year in the 1985-1989 cohort to 67 year in the 1995-1999 cohort. • Crude RRT treated MM incidence increased from 0.4 pmp in the 1985-1988 cohort to 1.6 pmp in 1997-1999 cohort. • Figure 1 shows the trends in the ...

The new england journal of medicine n engl j med 354;10 www.nejm.org march 9, 2006 1021 original article Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma Bart Barlogie, M.D., Ph.D., Guido Tricot, M.D., Ph.D., Elias Anaissie, M.D., John Shaughnessy, Ph.D., Erik Rasmussen, M.S., Frits van Rhee, M.D., Ph.D., Athanasios Fassas, M.D., Maurizio Zangari, M.D., Klaus Hollmig, M.D., Mauricio Pineda-Roman, M.D., Choon Lee, M.D., Giampaolo Talamo, M.D., Raymond Thertulien, M.D., Ph.D., Elias Kiwan, M.D., Somashekar Krishna, M.D., Michele Fox, M.D., and John Crowley, Ph.D. From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock (B.B., G.T., E.A., J.S., F.R., A.F., M.Z., K.H., M.P.-R., C.L., G.T., R.T., E.K., S.K., M.F.); and Can- cer Research and Biostatistics, ...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORTGROUP “Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.” NOVEMBER NOTES Meeting: Tuesday, November 18, 2003 UW Health – West Clinic Time: 3:30 – 5:30 PM 451 Junction Road Madison, WI 53717-2656 Program: Cindy Starks, Nutrition Educator Natural Ovens Bakers More Information: Chuck Koval &n...

Multiple myeloma Multiple myeloma is cancer of the plasma cells in bone marrow. Bone marrow is the soft tissue inside bones. The bone marrow makes blood cells. Blood is mostly made up of plasma. Floating in the plasma are: • Red blood cells – that carry oxygen around the body • White blood cells – that fight disease and infection • Platelets – that help to stop bleeding when it starts. When a person has multiple myeloma , too many plasma cells are made. Limited space inside the bone marrow means that fewer normal blood cells are made. This prevents normal levels of antibodies from being made, so you are less able to fight infections. Multiple myeloma spreads from the bone marrow into the bone, causing the bone to become thin, weak and more likely to break. The breakdown of the bone can cause an increase in the level of calcium ...

1 Highlights from Novel Therapeutic Avenues in Myeloma : Changing the Paradigm (Clinical Science Symposium) Rafael Fonseca, MD Mayo Clinic Scottsdale, Arizona Newly Diagnosed Multiple Myeloma Page 2 2 PN=Peripheral Neuropathy Anderson K, et al. ASCO 2006, Abstract 7504. Single-Agent Bortezomib in Newly Diagnosed MM Study Objectives • Primary – Overall Response Rate • Secondary – Time-to-progression – Safety – Incidence and severity of PN – Impact of dose modifications on PN – Effect of pharmacologic interventions on PN Dispenzieri A, et al. Blood . 2005;106. Abstract 2546. Jagannath S, et al. Blood . 2005;106. Abstract 783. Single-Agent Bortezomib for Patients With Newly Diagnosed MM 41% 16/40 Bortezomib ...

1 Highlights From the Oral Abstract Session on Multiple Myeloma Sagar Lonial, MD Winship Cancer Institute Emory University Atlanta, Georgia Newly Diagnosed Multiple Myeloma Page 2 2 Bladé Criteria Rajkumar SV, et al. ASCO 2006, Abstract 7517. Thal/Dex as Initial Therapy for Newly Diagnosed MM Patients Response Rate (%) 4.7 43.8 1.3 34 0 20 40 60 Thal/Dex Dex PR (>50%) CR (IF-) * p <.01 48.5%* 35.3%* Response Rate Rajkumar SV, et al. ASCO 2006, Abstract 7517. Thalidomide/dexamethasone Median TTP: not reached Dexamethasone alone Median TTP: 8.1 months 0.2 0.4 0.6 0.8 1.0 0 6 12 18 ...

29 INTRODUCTION Extramedullary plasmacytomas are rare lesions to diagnose, either as a part of a generalized disease (Multiple myeloma ) or a local entity. It is possible for an apparent solitary plasmacytoma to be the first presenting feature of generalized disease. Extramedullary plasmacytomas occurring as solitary (primary) tumors or secondary manifestations of multiple myeloma most often involve the upper airways and paranasal sinuses. Skull base is one of the rarest sites of extramedullary plasmacytoma. The imaging findings associated with this rare site of extramedullary plasmacytoma involvement are reported. CASE REPORT A 65-year-old woman presented with a large mass in the left submandibular region in the neck with asymmetry of left side of face and diplopia for six months. On examination of neck, a single diffuse 6x10 cm sized firm, non-tender swelling was noted over ...

haematologica/the hematology journal | 2006; 91(7) | 941 | Bjarne Bogen Pier Adelchi Ruffini Alexandre Corthay Agnete B. Fredriksen Marianne Frøyland Katrin Lundin Egil Røsjø Keith Thompson Massimo Massaia Idiotype-specific immunotherapy in multiple myeloma : suggestions for future directions of research H igh-dose chemotherapy and autolo- gous 1 and allogeneic 2,3 stem cell trans- plantation and new drugs such as thalidomide and bortezomib 4,5 have improved the treatment of multiple myelo- ma (MM). Despite this, MM is still consid- ered an essentially incurable cancer 6 and new therapies are undoubtedly warranted. This paper reviews immunotherapy approaches in MM with special emphasis on idiotype as a tumor-specific antigen to raise tumor-specific immune responses. ...

| 964 | haematologica/the hematology journal | 2006; 91(7) Giampaolo Talamo Federica Cavallo Maurizio Zangari Bart Barlogie Choon-Kee Lee Mauricio Pineda-Roman Elias Kiwan Somashekar Krishna Guido Tricot Clinical and biological features of multiple myeloma involving the gastrointestinal system I nvolvement of the gastrointestinal (GI) sys- tem in the course of multiple myeloma (MM) is extremely rare, and has been described in the medical literature mainly as case reports of single patients. In this study, we retrospectively identified 24 MM patients with direct infiltration of the GI system by MM cells documented by biopsy. We exclud- ed patients with other forms of GI involve- ment by plasma cell dyscrasias, such as pri- mary extramedullary plasmacytomas, light chain deposition disease, and amyloidosis. We analyzed the ...